Skip navigation | go to home page of govt.nz
Site Map | FAQ | Glossary
| Health Links | Contact
 |
|
|
| Haematology |
| Acronym | Study Title | Ethics Reference | Principle Investigator |
Trial Co-ordinator |
Study Status |
|---|---|---|---|---|---|
| Acute LymphoBLASTIC Leukaemia | |||||
 |
mEDICAL RESEARCH COUNCIL acute lymphoblastic leukaemia
trial ukallxii PROTOCOL NUMBER: MRC UKALL12 |
MREC/ 02/2/84 |
Dr Ruth Spearing | Jo Sanders | closed |
| ACUTE MYELOID LEUKAEMIA | |||||
 |
MEDICAL RESEARCH COUNCIL AML 15 FOR PATIENTS AGED UNDER 60YEARS. PROTOCOL NUMBER: AML15 |
MEC/ 02/05/072 |
Dr Ruth Spearing | Jo Sanders | closed |
 |
A PHASE 3, RANDOMIZED, DOUBLE BLIND, MULTI-CENTRE STUDY OF PROTEINASE 3 PR1 PEPTIDE MIXED WITH MONATIDE ISA51 VG ADJUVANT AND ADMINISTERED WITH GM-CSF IN ELDERLY PATIENTS WITH AML IN FIRST COMPLETE REMISSION OR ADULTS IN SECOND COMPLETE REMISSION: A PIVOTAL STUDY. | Dr Ruth Spearing | Jo Sanders | closed | |
 |
AN OPEN LABEL RANDOMIZED, CONTROLLED DOSE ESCALATING PHASE II STUDY OF AS1411 COMBINED WITH CYTARABINE IN THE TREATMENT OF PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE MYELOID LEUKAEMIA (AS1411-C-201) | Dr Ruth Spearing | Jo Sanders | closed | |
| AMYLOIDOSIS | |||||
|
A PHASE II STudy OF RISK-ADAPTED IV MELPHALAN IN PATIENTS
WITH AL AMYLOIDOSIS. PROTOCOL NUMBER: ALLG MM8 |
URA/ 07/07/052 |
Dr Steve Gibbons | Jo Sanders | closed |
| CHRONIC LYMPHOCYTIC LEUKAEMIA | |||||
 |
PHASE III TRIAL OF COMBINED
IMMUNOCHEMOTHERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB
(FC-R) VERSUS CHEMOTHERAPY WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (FC)
ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED CLL. PROTOCOL NUMBER: CLL-/ML17102 |
MEC/ 05/01/015 |
Dr Peter Ganly | Jo Sanders | closed |
 (Biogen Idec Relapsed Study) |
A Randomized, Open-Label, Multicenter, Phase 2/3 Study to
Evaluate the Safety and Efficacy of Lumiliximab in Combination with
Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine,
Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic
Lymphocytic Leukemia |
Dr Peter Ganly | Jo Sanders | closed | |
(Roche Relapsed Study) |
AN OPEN LABEL,
MULTICENTRE, RANDOMISED, COMPARATIVE, PHASE III STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF RITUXIMAB PLUS FLUDARABINE AND CYCLOPHOSPHAMIDE (FCR)
VERSUS FLUDARABINE AND CYCLOPHOSPHAMIDE ALONE (FC) IN PREVIOUSLY TREATED
PATIENTS WITH CD20 POSITIVE B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) |
MEC/ 05/01/015 |
Dr Peter Ganly | Jo Sanders | closed |
| CHRONIC MYELOID LEUKAEMIA | |||||
 |
an open-label, multi-centre, expanded access study of
oral amn107 in adult patients with imatinib-resistant or intolerant
chronic myeloid leukaemia in blast crisis, accelerated phase or chronic
phase. PROTOCOL NUMBER: CAMN107A2109 |
MEC/ 06/11/149 |
Dr Peter Ganly | Jo Sanders | closed |
| IDIOPATHIC THROMBOCYTOPENIC PURPURA | |||||
|
EXTEND (ELTROMBOPAG EXTENDED DOSING STUDY): AN EXTENSION STUDY OF ELTROMBOPAG OLAMINE (sb-497115-GR) IN ADULTS WITH itp, PREVIOUSLY ENROLLED IN AN ELTROMBOPAG STUDY. PROTOCOL NUMBER: TRA105325 |
MEC/ 106/08/083 |
Dr Peter Ganly | Jo Sanders | closed |
|
a randomised, double-blind, placebo-controlled phase III
study, to evaluate the efficacy, safety and tolerability of eltrombopag
olamine (SB-497115-gr) a thrombopoietin receptor agonist, administered
for 6 months as oral tablets once daily in adult subjects with
previously treated chronic itp. PROTOCOL NUMBER: TRA102537 |
MEC/ 106/09/097 |
Dr Peter Ganly | Jo Sanders | closed |
| MULTIPLE MYELOMA | |||||
|
Bortezomib and Dexamethasone as treatment and maintenance for multiple myeloma relapse. pROTOCOL NUMBER: BOMer |
MEC/ 06/10/122 |
Dr Steve Gibbons | Jo Sanders | closed |
 |
a multi-centre randomised phase iii study of low-dose
thalidomide, prednisolone and zoledronic acid versus prednisolone and
zoledronic acid for post-asct maintenance therapy in patients with
multiple myeloma pROTOCOL nUMBER: ALLG MM6 |
CTY/ 02/05/070 |
Dr WN Patton | Jo Sanders | closed |
 |
An open-LABEL, RANDOMISED STUDY OF velcade/melphalan/prednisone
versus melphalan/prednisone in subjects with previously untreated
multiple myeloma PROTOCOL NUMBER: 26866138-MMY-3002 |
NTX/ 04/12/008 |
Dr Steve Gibbons | Jo Sanders | closed |
|
NON-HODGKIN'S LYMPHOMA |
|||||
|
A PHASE 1B/II, OPEN-LABEL, MULTICENTRE STUDY OF THE
SAFETY, PHARMACOKINETICS AND EFFICACY OF APO2L/TRAIL ADMINISTERED
INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR
AND OTHER LOW-GRADE, CD20+, B-CELL NON-HODGKIN'S LYMPHOMAS THAT HAVE
PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY PROTOCOL NUMBER: APO3585g |
NYT/ 07/01/008 |
Dr Peter Ganly | Jo Sanders | closed |
|
RANDOMIZED STUDY OF ICE PLUS RITUXIMAB (R-ICE) VERSUS
DHAP PLUS RITUXIMAB (R-DHAP) IN PREVIOUSLY TREATED PATIENTS WITH CD 20
POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, ELIGIBLE FOR TRANSPLANTATION
FOLLOWED BY RANDOMIZED MAINTENANCE TREATMENT WITH RITUXIMAB.
Protocol Number: 50-03B |
CTR/ 03/09/151 |
Dr Peter Ganly | Jo Sanders | closed |
|
Randomised study of rituximab (MabThera) in patients with
relapsed or resistant follicular lymphoma prior to high dose therapy as
in vivo purging and to maintain remission following high dose
therapy. Protocol number: ebmtlym1 |
MEC/ 99/09/116 |
Dr Peter Ganly | Jo Sanders | closed |
|
A multi-centre phase III open-label randomised study in
patients with advanced follicular lymphoma evaluating the benefit of
maintenance therapy with rituximab in comparison with no maintenance
therapy. protocol number: nhl16 |
MEC/ 05/03/032 |
Dr Peter Ganly | Jo Sanders | closed |
|
NHL14 Trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). Protocol Number: NHL14 |
MEC/ 07/02/027 |
Dr Andrew Butler | Jo Sanders | closed |
| FUNGAL DISEASE | |||||
|
A PHASE III, DOUBLE BLIND, RANDOMISED STUDY TO EVALUATE
SAFETY AND EFFICACY OF BAL8557 VERSUS VORICONAZOLE FOR PRIMARY TREATMENT
OF INVASIVE FUNGAL DISEASE CAUSED BY ASPERGILLUS SPECIES OR OTHER
FILAMENTOUS FUNGI. pROTOCOL NUMBER:WSA-CS-004 |
MEC/ 07/04/054 |
Dr Andrew Butler | Jo Sanders | closed |
| SUPPORTIVE CARE | |||||
 |
A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL EVALUATING THE SAFETY AND EFFICACY OF RI-001 IN MEDICALLY IMMUNOSUPPRESSED RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTED PATIENTS AT RISK OF LOWER TRACT RSV ILLNESS. | Dr Steve Gibbons | Jo Sanders | closed | |
 |
A MULTICENTRE RANDOMISED CONTROLLED TRIAL COMPARING
TWO STRATEGIES FOR THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN HIGH-RISK
HAEMATOLOGY PATIENTS PROTOCOL NUMBER: SC01 |
Dr Liam Fernyhough | Jo Sanders | closed | |
| TRANSPLANT | |||||
 |
compassionate use protocol for the use of amd3100 to mobilise peripheral blood stem cells for collection and transplantation. PROTOCOL NUMBER:AMD3100-CUP001 |
URB/ 106/09/061 |
Dr Peter Ganly | Jo Sanders | closed |